Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Cocrystal Pharma Inc (COCP)

Cocrystal Pharma Inc (COCP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 69,690
  • Shares Outstanding, K 97,469
  • Annual Sales, $ 2,010 K
  • Annual Income, $ -9,650 K
  • 60-Month Beta 1.13
  • Price/Sales 36.93
  • Price/Cash Flow N/A
  • Price/Book 0.92
Trade COCP with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.13
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/15/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate -0.04
  • Number of Estimates 2
  • High Estimate -0.04
  • Low Estimate -0.04
  • Prior Year -0.01
  • Growth Rate Est. (year over year) -300.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7000 +2.14%
on 12/03/21
0.9960 -28.21%
on 11/08/21
-0.2370 (-24.89%)
since 11/03/21
3-Month
0.7000 +2.14%
on 12/03/21
1.1599 -38.36%
on 09/07/21
-0.4250 (-37.28%)
since 09/03/21
52-Week
0.7000 +2.14%
on 12/03/21
3.4600 -79.34%
on 05/04/21
-0.9250 (-56.40%)
since 12/03/20

Most Recent Stories

More News
Cocrystal Pharma to Discuss Progress with COVID-19 Antiviral Programs and Clinical Strategy During Noble Capital Markets’ Channelchek Virtual Roadshow

BOTHELL, Wash., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that President and...

COCP : 0.7150 (-6.30%)
Cocrystal Pharma Presents Preclinical Data from COVID-19 Antiviral Programs and Outlines Near-Term Clinical Plans at the World Antiviral Congress 2021

Unveils designs for Phase 1 and 2 studies with intranasal/pulmonary and oral SARS-CoV-2 protease inhibitors; trial initiations expected in 2022 BOTHELL,...

COCP : 0.7150 (-6.30%)
Cocrystal Pharma, Inc. (COCP) Reports Q3 Loss, Lags Revenue Estimates

Cocrystal Pharma, Inc. (COCP) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?...

COCP : 0.7150 (-6.30%)
Will Cocrystal Pharma, Inc. (COCP) Report Negative Q3 Earnings? What You Should Know

Cocrystal Pharma, Inc. (COCP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

COCP : 0.7150 (-6.30%)
Cocrystal Pharma’s SARS-CoV-2 Main Protease Inhibitors Demonstrate Pan-viral Activity against Human Common Coronaviruses, Noroviruses, Rhinoviruses, and Enteroviruses

BOTHELL, Wash., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that its SARS-CoV-2 main...

COCP : 0.7150 (-6.30%)
Cocrystal Pharma Submits Pre-Investigational New Drug Briefing Package to the FDA for Clinical Development Guidance of CDI-45205 for COVID-19 Treatment

FDA’s response is expected to provide greater clarity and guidance on designing Phase 1 and Phase 2 clinical trials for CDI-45205 BOTHELL, Wash., Nov....

COCP : 0.7150 (-6.30%)
Cocrystal Pharma to Present at the Dawson James 2021 Small Cap Growth Conference on October 21, 2021

BOTHELL, Wash., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology...

COCP : 0.7150 (-6.30%)
Cocrystal Pharma Receives Australian Regulatory Clearance to Initiate Phase 1 Study of CC-42344 for the Treatment of Pandemic and Seasonal Influenza

BOTHELL, Wash., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology...

COCP : 0.7150 (-6.30%)
Cocrystal Pharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

BOTHELL, Wash., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company, announces that management will...

COCP : 0.7150 (-6.30%)
New COVID-19 Vaccination Mandates Make Rapid COVID Tests More Essential Than Ever

FN Media Group Presents Microsmallcap.com Market Commentary

SIXWF : 0.1953 (+3.01%)
SIXW.CN : 0.250 (+2.04%)
CODX : 8.35 (-0.95%)
COCP : 0.7150 (-6.30%)
MRK : 73.34 (-0.74%)
MRNA : 306.72 (+1.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise...

See More

Key Turning Points

3rd Resistance Point 0.8267
2nd Resistance Point 0.7983
1st Resistance Point 0.7567
Last Price 0.7150
1st Support Level 0.6867
2nd Support Level 0.6583
3rd Support Level 0.6167

See More

52-Week High 3.4600
Fibonacci 61.8% 2.4057
Fibonacci 50% 2.0800
Fibonacci 38.2% 1.7543
Last Price 0.7150
52-Week Low 0.7000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar